Progenics Pharmaceuticals, Inc. (PGNX) Reports In-Line Q1 Loss

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) reported Q1 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $1.8 million versus the consensus estimate of $2.88 million.

For earnings history and earnings-related data on Progenics Pharmaceuticals, Inc. (PGNX) click here.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• NextPlat Corp (NXPL) Reports Q2 Loss of $0.05